| Bioactivity | Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects[1]. | ||||||||||||
| Invitro | Medroxalol (0.1-10 μM; 20 min) shows α- and β-adrenergic receptor antagonism in isolated rabbit aortic strip[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| In Vivo | Medroxalol (oral gavage; 12.5-50 mg/kg; once daily; 12 d) treatment shows antihypertensive activity in spontaneously hypertensive rats[1]. Animal Model: | ||||||||||||
| Name | Medroxalol | ||||||||||||
| CAS | 56290-94-9 | ||||||||||||
| Formula | C20H24N2O5 | ||||||||||||
| Molar Mass | 372.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Dage RC, et al. Cardiovascular properties of medroxalol, a new antihypertensive drug. J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):299-315. |